Today

Agents

Chat

Arena

Discover

More

App

Belite Bio completes FDA filing for tinlarebant in Stargardt disease type 1 - BLTE News | Rallies

Belite Bio completes FDA filing for tinlarebant in Stargardt disease type 1

BLTE•2026-07-20

FDA filing completed for tinlarebant

Belite Bio completed a New Drug Application filing with the FDA for tinlarebant to treat Stargardt disease type 1.

Related News

Anixa Biosciences director Lewis H. Titterton Jr acquires 12,000 common shares valued at $41,640

ANIX•2026-07-20

Mara Holdings General Counsel Nowaid Zabi disposes of 8,376 common shares for $100,512

MARA•2026-07-20

Houthis announce Saudi naval blockade, threatening new front in US-Iran war

XLE•2026-07-20

Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky disposes of 5,000 shares for $115,000

ADPT•2026-07-20

Nasdaq trade halt continues <PC.O> reason not available at 07:50 PM

PC•2026-07-20